Drawing for FIRMIO

USPTO serial 79268420

FIRMIO

Reviewed by CopyMark Law Group

Reg. 6004739Status 404
Filing date
Status date
Registration date
Mar 10, 2020
Examiner
BICE, DANIEL TRAVIS
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with FIRMIO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRIVERALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 22, 2023DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
May 22, 2023DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
May 21, 2023DETHDEATH OF INTERNATIONAL REGISTRATION—
Jul 31, 2020FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 16, 2020FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 16, 2020FIMPFINAL DISPOSITION PROCESSED—
Jun 10, 2020FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 10, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 3, 2020GPNXNOTIFICATION PROCESSED BY IB—
Dec 24, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 24, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 18, 2019OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 18, 2019OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Dec 4, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 15, 2019ALIEASSIGNED TO LIE—
Nov 15, 2019RFNTREFUSAL PROCESSED BY IB—
Nov 13, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 5, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 4, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 4, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 28, 2019RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 28, 2019RFRRREFUSAL PROCESSED BY MPU—
Oct 16, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 16, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 8, 2019RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 8, 2019MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 7, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 4, 2019DOCKASSIGNED TO EXAMINER—
Oct 4, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 27, 2019LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Sep 26, 2019SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance